Cytokinetics, Incorporated (CYTK)

NASDAQ: CYTK · Real-Time Price · USD

Compare

62.34

+2.10 (3.49%)

At close: Feb 6, 2026, 4:00 PM EST

61.00

-1.34 (-2.15%)

After-hours: Feb 6, 2026, 7:39 PM EST

Cytokinetics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	225.47	94.86	113.02	65.58	112.67	82.99
Short-Term Investments	737.07	981.16	501.8	717	358.97	381.08
Cash & Short-Term Investments	962.54	1,076	614.82	782.58	471.64	464.06
Cash Growth	-4.86%	75.01%	-21.44%	65.93%	1.63%	106.15%
Accounts Receivable	1.81	16.65	1.28	0.15	56.82	6.92
Receivables	1.81	16.65	1.28	0.15	56.82	6.92
Prepaid Expenses	13.01	15.28	11.94	12.46	7.22	3.24
Total Current Assets	977.35	1,108	628.05	795.19	535.67	474.22
Property, Plant & Equipment	153.58	140.97	147.74	163.19	146.41	16.27
Long-Term Investments	288.82	145.06	40.53	46.71	152.05	36.95
Other Long-Term Assets	16.81	7.71	8	9.69	7.19	6.36
Total Assets	1,437	1,402	824.32	1,015	841.32	533.8
Accounts Payable	22.08	20.37	21.51	25.61	21.09	8.05
Accrued Expenses	61.63	55.32	42.64	44.1	34.37	19.32
Short-Term Debt	16.9	11.3	-	-	-	-
Current Portion of Long-Term Debt	17.28	11.52	10.08	0.96	-	-
Current Portion of Leases	20.65	19.18	17.89	12.83	14.86	2.79
Current Unearned Revenue	1.61	52.37	-	-	-	-
Other Current Liabilities	1.99	9.61	10.56	1.12	1.54	1.05
Total Current Liabilities	142.14	179.67	102.68	84.62	71.86	31.2
Long-Term Debt	1,185	768.6	607.37	609.62	142.84	135.71
Long-Term Leases	110.66	112.58	120.43	126.9	112.23	0.44
Long-Term Unearned Revenue	504.5	462.19	379.98	300.5	266.07	253.07
Other Long-Term Liabilities	15.61	14	0.19	1.04	4.46	-
Total Liabilities	1,958	1,537	1,211	1,123	597.46	420.42
Common Stock	0.12	0.12	0.1	0.09	0.08	0.07
Additional Paid-In Capital	2,782	2,564	1,726	1,482	1,452	1,105
Retained Earnings	-3,304	-2,702	-2,112	-1,586	-1,208	-992.31
Comprehensive Income & Other	0.03	2.4	-0.01	-3.59	-0.87	0.15
Shareholders' Equity	-521.12	-135.37	-386.32	-107.9	243.86	113.38
Total Liabilities & Equity	1,437	1,402	824.32	1,015	841.32	533.8
Total Debt	1,350	923.18	755.77	750.3	269.93	138.94
Net Cash (Debt)	-387.72	152.83	-140.95	32.28	201.71	325.12
Net Cash Growth	-	-	-	-84.00%	-37.96%	265.13%
Net Cash Per Share	-3.26	1.36	-1.46	0.36	2.62	5.04
Filing Date Shares Outstanding	122.26	118.41	103	95.16	84.86	71.11
Total Common Shares Outstanding	122.26	118.21	101.64	94.83	84.8	71.02
Working Capital	835.21	928.27	525.37	710.57	463.81	443.02
Book Value Per Share	-4.26	-1.15	-3.80	-1.14	2.88	1.60
Tangible Book Value	-521.12	-135.37	-386.32	-107.9	243.86	113.38
Tangible Book Value Per Share	-4.26	-1.15	-3.80	-1.14	2.88	1.60
Machinery	-	30.82	28.16	28.45	27.48	22.99
Construction In Progress	-	4.07	0.22	0.74	0.22	9.13
Leasehold Improvements	-	66.87	66.87	65.91	60.34	5.87

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q